The administrative handling of regulatory oversight procedures differs from
country to country, whereas the scientific data required for the safety as
surance are similiar in most instances. Safety issues for contained biotech
nology applications are mainly a matter between industry and the government
agencies involved. Deliberate release of transgenic organisms and the mark
et introduction of transgenic food, however, produce much public debate. It
is assumed that shortcomings related to risk-assessment methodology as, e.
g., the lack of accepted protection goals and the continuing discussions ab
out the validity of comparative risk assessment may be reasons for the curr
ent situation.